賽生藥業(06600.HK)上半年淨利潤6.23億元 研發開支同比增加31.8%
格隆匯8月20日丨賽生藥業(06600.HK)發佈公吿,截至2021年6月30日止六個月,收入約為人民幣13.313億元,較去年同期增長約14.7%; 毛利同比增長約13.0%至約人民幣10.459億元; 淨利潤約為人民幣6.227億元,比去年同期上升約4.3%;每股基本盈利約為人民幣0.99元。
公吿表示,儘管仍然存在挑戰、風險及不確定因素,集團仍能把握宏觀環境,妥善實施集團的策略。集團的產品銷售保持強勁增長勢頭,集團的創新在研藥物DANYELZA®(那西妥單抗)實現更快的上市時間,集團的“Go-To-Patient”創新模式繼續蓬勃發展。集團的研發開支由去年同期的人民幣3000萬元增加31.8%至2021年上半年的人民幣3950萬元。隨着銷售及開發團隊的擴大,僱員福利增加10.8%。此外,2020年上半年,由於COVID-19的影響,研發活動被推遲或取消,而自2020年下半年起,研發活動逐漸從該影響中恢復並增長。此勢頭延續至2021年上半年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.